IMPAHCT Study Investigates a New Treatment for Pulmonary Hypertension
Trial Objectives
Pulmonary arterial hypertension (PAH), or high blood pressure in the lungs, is a serious condition that makes it more difficult for the heart to pump blood through the body. Current treatment options help relieve PAH symptoms, but do not target the underlying causes of the condition. The IMPAHCT clinical trial is evaluating an investigational medication for pulmonary arterial hypertension (PAH) called AV-101 to find out what dose is safe and tolerable, and works best in people with PAH.
Study participants will take either AV-101 or a placebo (a treatment containing no active medication) twice a day. During study visits or phone calls, participants will complete assessments to help researchers understand how the medication may be helping them and any side effects that might occur. Participants can continue taking any PAH medications they are currently taking.
Who Can Participate
Adults ages 18-75 with a documented pulmonary arterial hypertension (PAH) diagnosis, who have been receiving a minimum of two PAH medications for at least 90 days.
Age: 18-75 Gender: Any
Estimated Time Commitment
Five study visits over 24 weeks, plus an introductory screening visit and four phone calls
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Contact
For more information, contact:
Jennifer Underwood
303.398.1518
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Aerovate Therapeutics, Inc.
Principal Investigators
Marjorie Patricia George, MD
Co-Investigators
-
Darlene Kim, MD, FACC
-
Vera Pillitteri, DNP, FNP-BC